Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II
India, April 24 -- Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI), highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis.MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The two publications offer complementary insights into MM-II's clinical efficacy and mechanism of action, underscoring its potential therapeutic value.The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled...
To read the full article or to get the complete feed from this publication, please
Contact Us.